What are the benefits and risks of treating premenstrual syndrome and premenstrual dysphoric disorder with selective serotonin reuptake inhibitors?

In August 2024, we published the latest update of the Cochrane Review of the effect of selective serotonin reuptake inhibitors on women with premenstrual syndrome and premenstrual dysphoric disorder. In this podcast, two of the authors, Jeppe Bennekou Schroll and Cecilie Jespersen, both from Cochrane Denmark, talk about the need for the review and its latest findings.